Shilpa Medicare’s arm enters into strategic partnership with Orion Corporation

23 May 2025 Evaluate

Shilpa Medicare’s 100% subsidiary -- Shilpa Biocare has entered into a strategic partnership with Orion Corporation (Orion), a globally recognized pharmaceutical company headquartered in Finland, out-licensing its flagship product -- Recombinant Human Albumin -- for commercialisation across the European market. The product is currently under development.

Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. Shilpa has been investing in the development of this novel product for about 8 years and has also set-up a large scale fermentation facility for manufacture of recombinant human albumin to address market demand for this life saving drug at a global scale. This collaboration marks a major milestone in Shilpa’s expansion into global biosimilar and biopharmaceutical markets, leveraging Orion’s strong regional presence, regulatory expertise, and well-established commercial infrastructure.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

319.85 -0.65 (-0.20%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×